Anti-obesity drug also protects against heart disease — what happens next?

Clinical-trial data suggest that semaglutide, sold under the name Wegovy, slashes risk of heart attacks and other cardiovascular incidents. Clinical-trial data suggest that semaglutide, sold under the name Wegovy, slashes risk of heart attacks and other cardiovascular incidents.

Related Keywords

California ,United States ,Denmark ,New York ,Stanford University ,Maryland ,Baltimore ,American ,Martha Gulati ,Richard Levine Alamy ,Michael Blaha ,Los Angeles ,Beverly Tchang ,Joseph Wu ,Drug Administration ,Sinai Medical Center ,American Heart Association ,Johns Hopkins Ciccarone Center ,Stanford University School Of Medicine ,Novo Nordisk ,Cardiovascular Disease ,Cedars Sinai Medical Center ,Stanford University School ,Weill Cornell Medicine ,